menu
    • menu
    [{"orgOrder":0,"company":"ProLynx","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ National Cancer Institute"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"7-Ethyl-10-Hydroxycamptothecin","moa":"||DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"ProLynx","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"PLX038","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ProLynx \/ ProLynx","highestDevelopmentStatusID":"8","companyTruncated":"ProLynx \/ ProLynx"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"PLX038","moa":"DNA topoisomerase I","graph1":"Oncology","graph2":"Phase I","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ Undisclosed"},{"orgOrder":0,"company":"ProLynx","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Funding","leadProduct":"Teriparatide","moa":"Parathyroid hormone receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"ProLynx \/ National Institutes of Health"},{"orgOrder":0,"company":"ProLynx","sponsor":"Robert Flavell, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"89-Zr DFO-Star Polyethylene Glycol","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"ProLynx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProLynx \/ Robert Flavell, MD, PhD","highestDevelopmentStatusID":"6","companyTruncated":"ProLynx \/ Robert Flavell, MD, PhD"}]

    Find Clinical Drug Pipeline Developments & Deals by ProLynx

    Menu

    ProLynx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 89-Zr DFO-Star Polyethylene Glycol

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Robert Flavell, MD, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PET [89Zr]DFO-starPEG in Solid Tumors

                            Details : 89-Zr DFO-Star Polyethylene Glycol is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            March 25, 2025

                            Lead Product(s) : 89-Zr DFO-Star Polyethylene Glycol

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Robert Flavell, MD, PhD

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Unveils Monthly Dosing Preclinical Results for Long-Acting Semaglutide

                            Details : Semaglutide is a peptide GLP-1 agonist, peptide drug candidate, which is being evaluated for the treatment of type 2 diabetes & obesity.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Initiates Phase II of PLX038 in Triple-Negative Breast Cancer at Institut Curie

                            Details : PLX038 is a long-acting prodrug of the topoisomerase 1 (Top1) inhibitor, SN-38. It is being evaluated for the treatment of locally-advanced or metastatic triple-negative breast cancer.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            March 25, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Initiates Phase I/II of PLX038 in Rare CNS Tumors at National Cancer Institute

                            Details : PLX038 is a long-acting prodrug of the topoisomerase 1 inhibitor, It is being evaluated in phase 1/2 clinical trials for the treatment of primary CNS tumors driven by MYC or MYCN amplifications.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 05, 2024

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX038

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Institut Curie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Efficacy and Toxicities of PLX038, in Patients With Locally Advanced or Metastatic Tri...

                            Details : PLX038 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 08, 2023

                            Lead Product(s) : PLX038

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Institut Curie

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx Announces Initiation Of Phase II Clinical Trial Of Its DNA-Damaging Agent PLX038 in Patients With Plat...

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            October 07, 2022

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Cancer Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            ProLynx announces SBIR Arant Award to Develop Long-Ating Parathyroid Hormone for Hypo-Parathyroidism

                            Details : The grant was conferred for the development of a long acting parathyroid hormone – PTH(1-34) – that can be administered once-weekly for treatment of hypo-parathyroidism.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            July 07, 2020

                            Lead Product(s) : Teriparatide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ProLynx announces Phase 1B clinical trial of its DNA-damaging agent PLX038 (PEG~SN-38)

                            Details : PLX038 (PEG~SN-38) is a long-acting PEGylated prodrug of SN-38, the active metabolite of the approved anti-cancer agents irinotecan and Trodelvy® (sacituzumab govitecan). SN-38 is a potent inhibitor of topoisomerase 1 (topo1) that causes inhibition of D...

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 13, 2020

                            Lead Product(s) : 7-Ethyl-10-Hydroxycamptothecin,Rucaparib Camsylate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            ProLynx

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PLX038

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase I Study of PLX038 in Patients With Advanced Solid Tumors

                            Details : PLX038 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            January 06, 2016

                            Lead Product(s) : PLX038

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth